All subcategories » congress abstract
Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways
primary studies congress abstract
Details- 2019
- Taccetti G
The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial
primary studies congress abstract
Details- 2018
- Dentice RL
A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)
primary studies congress abstract
Details- 2018
- Loebinger M
Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial
primary studies congress abstract
Details- 2018
- Radtke T
MOOD AND PHYSICAL ACTIVITY OF CYSTIC FIBROSIS PATIENTS IN INPATIENT EXERGAMING PROGRAM
primary studies congress abstract
Details- 2018
- Bessette HC
Effects of tezacaftor/ivacaftor treatment in patients with cystic fibrosis and F508DEL/ F508DEL-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial
primary studies congress abstract
Details- 2018
- Yang Y
Effect of a wearable fitness tracker on exercise tolerance for adults with cystic fibrosis: a pilot randomized clinical trial
primary studies congress abstract
Details- 2018
- Bishay LC
An observational study of ivacaftor in patients with cystic fibrosis and selected non-G551D gating mutations in UK, Italy and Netherlands: healthcare resource utilization from the first interim analysis of the vocal study
primary studies congress abstract
Details- 2018
- Castellani C
Effects of GLP-1 and GIP on insulin secretion in glucose intolerant, pancreatic insufficient cystic fibrosis
primary studies congress abstract
Details- 2018
- Eiel JN
A single dose of a novel nebulised pde3/4 inhibitor rpl554 increased fev1 in patients with cystic fibrosis and demonstrated a reproducible pharmacokinetic profile
primary studies congress abstract
Details- 2018
- Eneje OJ